Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New depression pill shows promise in quick mood lift

NCT ID NCT06267846

Symptom relief Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 2 trial tested an experimental drug called NBI-1070770 in 73 adults with major depressive disorder. Participants took the drug or a placebo for 5 days to see if it could quickly improve depression symptoms. The study is already completed, and results will show whether this approach is worth further testing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NBI-1070770
What this could lead to
If successful, this could point toward a fast-acting treatment for depression that works within days.
What could go wrong
This is a small, early-phase trial (73 people) testing a short-term effect. The drug may not outperform placebo, and long-term safety and efficacy are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

73 people

The number who actually took part.

Started

Mar 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: Participants must meet all of the following inclusion criteria: * Primary diagnosis of recurrent MDD or persistent MDD. * Participants currently receiving pharmacological treatment for depression must have been taking current antidepressant medication(s) for ≥8 weeks prior to screening and must be willing and able to continue with current antidepressant medication(s). * Participants must be willing and able to comply with all study procedures and restrictions. Key Exclusion Criteria: Participants will be excluded from the study if they meet any of the following criteria: * Participant is pregnant or breastfeeding or plan to become pregnant during the study. * Participant has an unstable medical condition or unstable chronic disease. * Participant has a history of neurological abnormalities. * Participant has a current or prior psychiatric disorder diagnosis that was the primary focus of treatment other than MDD. * Participant's depressive symptoms have previously demonstrated nonresponse to an adequate course of treatment with electroconvulsive therapy. * Participant has an alcohol or substance use disorder. Note: Other inclusion/exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder

Contacts and locations

Locations

  • Neurocrine Clinical Site

    Little Rock, Arkansas, 72211, United States

  • Neurocrine Clinical Site

    Rogers, Arkansas, 72758, United States

  • Neurocrine Clinical Site

    Lemon Grove, California, 91945, United States

  • Neurocrine Clinical Site

    Long Beach, California, 90806, United States

  • Neurocrine Clinical Site

    Hollywood, Florida, 33024, United States

  • Neurocrine Clinical Site

    Maitland, Florida, 32751, United States

  • Neurocrine Clinical Site

    Decatur, Georgia, 30030, United States

  • Neurocrine Clinical Site

    Savannah, Georgia, 31405, United States

  • Neurocrine Clinical Site

    Gaithersburg, Maryland, 20877, United States

  • Neurocrine Clinical Site

    Dayton, Ohio, 45439, United States

  • Neurocrine Clinical Site

    North Canton, Ohio, 44730, United States

  • Neurocrine Clinical Site

    Houston, Texas, 77008, United States

  • Neurocrine Clinical Site

    Richardson, Texas, 75080, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.